Julia Beck
Overview
Explore the profile of Julia Beck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
91
Citations
1517
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beck J, Hasenbohler F, Werlen L, Lengsfeld S, Meienberg A, Bathelt C, et al.
Eur J Prev Cardiol
. 2025 Mar;
PMID: 40037282
Aims: Cigarette smoking cessation reduces cardiovascular risk via various mechanisms. Thereby, the role of blood pressure remains unclear, with studies reporting both decreased and increase blood pressure values after cessation,...
2.
3.
4.
Akifova A, Budde K, Amann K, Buettner-Herold M, Choi M, Oellerich M, et al.
Nephrol Dial Transplant
. 2024 Dec;
PMID: 39673311
Background And Hypothesis: Donor-derived cell-free DNA (dd-cfDNA) shows good diagnostic performance for the detection of antibody-mediated rejection (AMR) in kidney transplant recipients (KTR). However, the clinical benefits of dd-cfDNA monitoring...
5.
Klinsing S, Beck J, Weber K, Bornemann-Kolatzki K, Dettki M, Urban H, et al.
Acta Neuropathol Commun
. 2024 Nov;
12(1):177.
PMID: 39568088
The gold standard for precise diagnostic classification of brain tumors requires tissue sampling, which carries relevant procedural risks. Brain biopsies often have limited sensitivity and fail to address tumor heterogeneity,...
6.
Atila C, Straumann I, Vizeli P, Beck J, Monnerat S, Holze F, et al.
JAMA Netw Open
. 2024 Nov;
7(11):e2445278.
PMID: 39546312
Importance: 3,4-Methylenedioxymethamphetamine (MDMA, or ecstasy) is a recreational drug being investigated for the treatment of posttraumatic stress disorder. Acute hyponatremia is a potentially serious complication after even a single dose...
7.
Akifova A, Budde K, Oellerich M, Beck J, Bornemann-Kolatzki K, Schutz E, et al.
Transpl Int
. 2024 Aug;
37:13239.
PMID: 39188271
Antibody-mediated rejection (AMR) is a major cause of graft failure limiting long-term graft survival after kidney transplantation. Current diagnostic strategy to detect AMR is suboptimal and requires further improvement. Previously...
8.
Donor-Derived Cell-Free DNA as a Companion Biomarker for AMR Treatment With Daratumumab: Case Series
Osmanodja B, Akifova A, Budde K, Oellerich M, Beck J, Bornemann-Kolatzki K, et al.
Transpl Int
. 2024 Aug;
37():13213.
PMID: 39149569
Antibody-mediated rejection (AMR) is among the most frequent causes for graft loss after kidney transplantation. While there are no approved therapies, several case reports with daratumumab and the very recent...
9.
Oltmer J, Mattern H, Beck J, Yakupov R, Greenberg S, Zwanenburg J, et al.
J Cereb Blood Flow Metab
. 2024 Jun;
44(11):1362-1377.
PMID: 38863151
Enlarged perivascular spaces (EPVS) are common in cerebral small vessel disease (CSVD) and have been identified as a marker of dysfunctional brain clearance. However, it remains unknown if the enlargement...
10.
Mayer K, Schrezenmeier E, Diebold M, Halloran P, Schatzl M, Schranz S, et al.
N Engl J Med
. 2024 May;
391(2):122-132.
PMID: 38804514
Background: Antibody-mediated rejection is a leading cause of kidney-transplant failure. The targeting of CD38 to inhibit graft injury caused by alloantibodies and natural killer (NK) cells may be a therapeutic...